PHASE II A
PHASE II B
SER140 targets newly-diagnosed patients as early as possible after they have been diagnosed with Type 1 Diabetes.
SER140, an IL-1 receptor antagonist, is expected to reduce the inflammatory cascade in Type 1 Diabetes (T1D), reduce apoptosis of pancreatic β-cells and increase peripheral insulin sensitivity. In vitro and in vivo studies have confirmed that SER140 significantly inhibited IL-1β-induced TNF-α secretion in macrophages. Furthermore, SER140 antagonised IL-1β-induced primary rat islet apoptosis, exceeding the antagonistic effect of the IL-1R protein blocker, anakinra (Kineret®). In an animal test model for T1D, administration of SER140 statistically significantly prevented development of T1D compared to placebo treatment (Cusak et al, 2016).
SER140 has shown beneficial pre-clinical effects by preventing development of T1D. It is anticipated that administration of SER140 to newly-diagnosed T1D patients could prevent apoptosis of the residual insulin-producing beta-cells. In this case, SER140 could maintain the blood glucose level within normal ranges and delay the intense, daily glucose testing. Further, administration of insulin could potentially be postponed.